Skip to main content
Scientific publications

At Day One, we use the power of leading-edge science to improve patient outcomes.

We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
May 2025
Growth recovery in patients with BRAF-altered pediatric low-grade gliomas (pLGGs) after discontinuation of tovorafenib 
Kline C, Wright KD, Kilburn LB, Chi SN, Landi DB, van der Lugt J, Leary SES, Abdelbaki MS, Bailey S, Nysom K, Khuong-Quang DA, Sayour E, Witt O, Driever PH, Larouche V, Bailey-Torres A, Ott L, Qiu J, McLeod LM, Mueller S.
Abstract 10029. Growth recovery in patients with BRAF-altered pediatric low-grade gliomas (pLGGs) after discontinuation of tovorafenib. Poster presentation at: ASCO (American Association for Clinical Oncology) Annual Meeting 2025; May 31, 2025; Chicago, IL.
May 2025
Post hoc analysis of rashes reported in patients (pts) with BRAF-altered relapsed/refractory (r/r) pediatric low-grade glioma (pLGG) treated with the type II RAF inhibitor tovorafenib in FIREFLY-1. 
Witt O, Chi SN, Hyoung JK, Ziegler DS, Baxter PA, Bailey S, Driever PH, Leary SES, McCowage G, Perreault S, Waanders AJ, Landi DB, Kilburn LB, Hansford JR, Khuong-Quang DA, Nysom K, Bailey-Torres A, Qiu J, McLeod LM, van der Lugt J.
Abstract 10037. Post hoc analysis of rashes reported in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma (pLGG) treated with the type II RAF inhibitor tovorafenib in FIREFLY-1. Poster presentation at: ASCO (American Association for Clinical Oncology) Annual Meeting 2025; May 31, 2025; Chicago, IL.
April 2025
Phase 1 dose escalation and expansion study of the PTK7-targeted antibody-drug conjugate DAY301 in patients with locally advanced or metastatic solid tumors. 
Sommerhalder D, Durm GA, Maki R, LoRusso PM, Piha-Paul SA, Bedard PL, Chau N, Venetsanakos E, Hume S, Qiu J, Martorana M, Kieran MW, Da Costa D, Lakhani N.
Abstract CT196. Phase 1 dose escalation and expansion study of the PTK7-targeted antibody-drug conjugate DAY301 in patients with locally advanced or metastatic solid tumors. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2025; April 29, 2025; Chicago, IL.
April 2025
Sequencing MEK inhibitor therapy after tovorafenib in BRAF fusion-driven cancers: Preclinical evidence of sustained tumor regression. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2025; April 28, 2025; Chicago, IL.
Perino S, Wang Y, Rastogi S, Damayanti NP, Pollok KE, Govinda Raju S, Kieran MW, Blackman SC, Venetsanakos E.
Abstract 1727. Sequencing MEK inhibitor therapy after tovorafenib in BRAF fusion-driven cancers: Preclinical evidence of sustained tumor regression. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2025; April 28, 2025; Chicago, IL.
March 2025
Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or an NF1-loss of function mutation
Rastogi S, Perino S, Lal-Nag M, Wang Y, Blackman SC, Eleni Venetsanakos E.
Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or an NF1-loss of function mutation [published online ahead of print March 20, 2025]. Cancer Res. Commun. 2025.
December 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang D-A, Gottardo NG, Hassall TE, Han JW, Oren MY, Chi SN, Qiu J, Da Costa D, Govinda Raju S, Manley P, Hargrave D.
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial [published online ahead of print December 19, 2024]. NeuroOncol. 2024.